Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies
An additional 202 articles were excluded for the following reasons: irrelevant study population (n=60), unrelated interventions (n=90), insufficient or incomplete data (n=52), and language limitations (non-English)
Patients Most people researching dermal fillers before-and-after results are not looking for a dramatic transformation
covered by current morning's lantus, diamicron MR and limited coverage from current morning's metformin
Very likely hundreds of thousands, perhaps even now into the millions, but we actually have essentially no human data as to how BPC-157 works in humans and why it does seem, because this seems to be the quote-unquote anecdata, to accelerate healing of a variety of different injuries